Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARB | P10826 | 5/20 | 0.71 |
| ▸ | TP53 | P04637 | 1/20 | 0.63 |
| ▸ | TSHR | P16473 | 1/20 | 0.63 |
| ▸ | PLA2G4B | P0C869 | 6/20 | 0.61 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.56 |
| ▸ | PPARG | P37231 | 3/20 | 0.55 |
| ▸ | PPARA | Q07869 | 1/20 | 0.55 |
| ▸ | THRA | P10827 | 1/20 | 0.53 |
| ▸ | THRB | P10828 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | NR5A1 | Q13285 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18314362 | 1.00 | RARB (0.71) | RARBTP53TSHRPLA2G4BPLA2G4A | |
| SCHEMBL677624 | 0.98 | RARB (0.68) | RARBTP53TSHRPLA2G4BPLA2G4A | |
| SCHEMBL19130711 | 0.95 | TP53 (0.69) | RARBTP53TSHRPLA2G4BPLA2G4A | |
| SCHEMBL7909288 | 0.95 | RARB (0.63) | RARBTP53TSHRPLA2G4B | |
| SCHEMBL13385664 | 0.95 | TP53 (0.69) | RARBTP53TSHRPLA2G4BPLA2G4A | |
| SCHEMBL19130183 | 0.95 | TP53 (0.69) | RARBTP53TSHRPLA2G4BPLA2G4A | |
| SCHEMBL19130182 | 0.94 | TP53 (0.66) | RARBTP53TSHRPLA2G4BPLA2G4A | |
| SCHEMBL9378715 | 0.91 | TSHR (0.60) | RARBTP53TSHRPLA2G4BGAA | |
| SCHEMBL10746659 | 0.89 | RARB (0.68) | RARBTP53TSHRPLA2G4BPLA2G4A | |
| SCHEMBL9327561 | 0.89 | RARB (0.68) | RARBTP53TSHRPLA2G4BPLA2G4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11654196-B2 | Dosing regimens for echinocandin class compounds | CIDARA THERAPEUTICS, INC. (US) | 2023-05-23 | — | — | US | disclosed |
| US-10702573-B2 | Dosing regimens for echinocandin class compounds | CIDARA THERAPEUTICS, INC. (US) | 2020-07-07 | — | — | US | disclosed |
| US-20190160141-A1 | DOSING REGIMENS FOR ECHINOCANDIN CLASS COMPOUNDS | SEACHAID PHARMACEUTICALS, INC. | 2019-05-30 | — | — | US | disclosed |
| US-10016479-B2 | Dosing regimens for echinocandin class compounds | CIDARA THERAPEUTICS, INC. (US) | 2018-07-10 | — | — | US | disclosed |
| US-20170151306-A1 | DOSING REGIMENS FOR ECHINOCANDIN CLASS COMPOUNDS | NAPP PHARMACEUTICAL GROUP LIMITED (GB) | 2017-06-01 | — | — | US | disclosed |
| US-9526835-B2 | Dosing regimens for echinocandin class compounds | CIDARA THERAPEUTICS, INC. (US) | 2016-12-27 | — | — | US | disclosed |
| WO-2016201283-A1 | ANTIFUNGAL AGENTS | CIDARA THERAPEUTICS, INC. (US) | 2016-12-15 | — | — | WO | disclosed |
| US-20150087583-A1 | DOSING REGIMENS FOR ECHINOCANDIN CLASS COMPOUNDS | CIDARA THERAPEUTICS, INC. (US) | 2015-03-26 | — | — | US | disclosed |
| US-20120190613-A1 | ECHINOCANDIN DERIVATIVES | JAMES JR KENNETH DUKE (US) | 2012-07-26 | — | — | US | disclosed |
| US-20120190613-A1 | ECHINOCANDIN DERIVATIVES | JAMES JR KENNETH DUKE (US) | 2012-07-26 | — | — | US | disclosed |
| US-7902148-B2 | Use of an echinocandin antifungal agent in combination with a glycopeptide antibacterial agent | THERAVANCE, INC. (US) | 2011-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10702573-B2 | Dosing regimens for echinocandin class compounds | XPO5, XPO1, CYP3A5 | RARB 4586/4885TP53 3992/4885TSHR 4692/4885 |
| US-11654196-B2 | Dosing regimens for echinocandin class compounds | XPO5, XPO1, CYP3A5 | RARB 4586/4885TP53 3992/4885TSHR 4692/4885 |
| US-10016479-B2 | Dosing regimens for echinocandin class compounds | XPO5, XPO1, CYP3A5 | RARB 4586/4885TP53 3992/4885TSHR 4692/4885 |
| US-20170151306-A1 | DOSING REGIMENS FOR ECHINOCANDIN CLASS COMPOUNDS | XPO5, XPO1, CYP3A5 | RARB 4586/4885TP53 3992/4885TSHR 4692/4885 |
| US-20150087583-A1 | DOSING REGIMENS FOR ECHINOCANDIN CLASS COMPOUNDS | XPO5, XPO1, CYP3A5 | RARB 4586/4885TP53 3992/4885TSHR 4692/4885 |
| US-20120190613-A1 | ECHINOCANDIN DERIVATIVES | ERG28, DPM1, EML4 | RARB 4179/4885TP53 1662/4885TSHR 4636/4885 |
| US-20190160141-A1 | DOSING REGIMENS FOR ECHINOCANDIN CLASS COMPOUNDS | XPO5, XPO1, CYP3A5 | RARB 4586/4885TP53 3992/4885TSHR 4692/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.